Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Battle lines are drawn in new Sorrell pay row

Article Abstract:

A dispute has arisen over a proposed pay deal for the chief executive of WPP, Martin Sorrell. Hermes and Flemings, both pension fund managers with stakes in WPP, plan to vote against this proposal which involves a 25 million pounds sterling bonus scheme. The Association of British Insurers has asked for a justification of the proposal. The UK government is concerned about public perceptions of executive pay levels on the UK and Sorrell argues that opposition is motivated by political reasons.

Author: Ahmad, Sameena
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Advertising Agencies, Compensation and benefits, WPP Group PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Must do better, ad men tell television chiefs: commercial TV companies are ploughing more money into the fight for viewers. But they're coping well with uppity advertisers and stiff competition

Article Abstract:

Advertisers are forcing independent television companies to review their schedules and increase programme making budgets because of the rising cost of airtime, which have coincided with a fall in ITV's television audience share. The companies will move blockbuster movies forward and invest in new programmes. However John Hooper, director general of the Incorporated Society of British Advertisers, is concerned that commercial companies are losing viewers to the BBC, which is more focused.

Author: Ahmad, Sameena
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Television Broadcasting, UHF-Independents, Services, Independent television stations, UHF television broadcasting

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A biotech shocker

Article Abstract:

Tarabetic, a treatment from Scotia for nerve damage caused by diabetes, has faied to be granted regulatory approval and this has led to a drop in the company's share price. The company had expected a rise in sales of 25 million pounds sterling from Tarabetic in 1997, and Tarabetic accounted for a fifth of Scotia's valuation. Analysts argue that the product is not likely to be approved, while the company sees approval as likely over the long term.

Author: Ahmad, Sameena
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1997
Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Central Nervous System Prep, Product development, Biotechnology industry, Biotechnology industries, Central nervous system agents, Scotia Holdings PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Similar abstracts:
  • Abstracts: Partnerships in African crop biotech. Partnering up in Q3. International regional collaborations are paying off
  • Abstracts: Good infrastructure helps draw potential investors. Pit closures prove serious loss to buoyant economy. Corporate finance set to pick up after slow 1994
  • Abstracts: UK: nearing the peak. UK interest rates: inflation shock
  • Abstracts: On the interrelation between production technology, job design, and incentives. Performance measurement systems, incentives, and the optimal allocation of responsibilities
  • Abstracts: Effective target tolerance in an inverted Fitts task. Concurrent manual-decision tasks. Data-entry keyboard geometry and keying movement times
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.